Professionals 243 Users Online

Fibromyalgia Antidepressants Market

Growing Prevalence of Chronic Pain and Musculoskeletal Indications will propel the Market for Fibromyalgia Antidepressants

Fibromyalgia Antidepressants Market Segmented By Venlafaxine, Duloxetine HCL, Milnacipran HCL Drug Class

Fibromyalgia Antidepressants Market Outlook (2023-2033)

The global revenue from the fibromyalgia antidepressants market stands at US$ 496.4 Mn in 2022, with the global market expected to grow at a CAGR of 8.3% to reach a valuation of approximately US$ 1,182.2 Mn by the end of 2033.

Attributes Key Insights

Market Size (2022)

US$ 496.4 Mn

Projected Market Value (2033)

US$ 1,182.2 Mn

Global Market Growth Rate (2023-2033)

8.3% CAGR

Market Share of Top 5 Countries

64.4%

As assessed by Persistence Market Research, duloxetine HCl antidepressants are expected to hold a market value of around US$ 831.2 Mn by 2033. Overall, fibromyalgia antidepressants market sales account for approximately 38.9% revenue share in the global fibromyalgia market, which was valued at around US$ 1.3 Bn in 2022.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Sales Analysis of Fibromyalgia Antidepressants Market from 2016 to 2022 Vs Market Outlook for 2023 to 2033

The global market recorded a historic CAGR of 4.7% in the last 6 years from 2016 to 2022.

In contrast to other syndromes, fibromyalgia (FM) lacks a clear-cut underlying organic pathology. FM is a condition that requires a positive diagnosis rather than a diagnosis of exclusion and has been linked to illnesses like diabetes, mental or neurological diseases, rheumatic disorders, and infections.

The treatment of FM necessitates a multifaceted strategy that includes pain control, medication, behavioural therapy, proper patient adherence to treatment, and exercise.

FM is currently diagnosed using the broad pain index and a score for the severity of cognitive symptoms, restless sleep, and fatigue. The exact origin of FM is unknown, however identifying FM helps patients deal with polysymptomatic distress by minimizing the doubt and anxiety that are the two main psychological components causing this central amplification mechanism.

2018 opened a new door to a comprehensive and true understanding of FM diagnosis, beyond the current arbitrary and constructional scores, by taking into account significant but less obvious aspects that have a substantial impact on under- or over-diagnosis of FM.

In order to distinguish FM from pain that is secondary to an underlying disease, an IASP Working Group developed a classification system that has been incorporated into the International Classification of Diseases (ICD-11) in collaboration with the WHO. FM has been classified as chronic primary pain under this system.

According to the 2018 Cochrane Database Systematic Review, approximately 25% to 40% of people take painkillers to reduce their pain, and only 40% to 60% get substantial alleviation. This is partly because to dose-limiting side effects and insufficient pharmacological efficacy. Due to these shortcomings in clinical practise, some have proposed that combining various analgesics that work via various mechanisms may result in better outcomes than monotherapy.

Additionally, because some individuals either are unable to withstand or respond from drug therapy, antidepressants should be introduced at lower doses and gradually increased. Drugs should be chosen to control the person's major symptoms as sleep disturbance, pain, and psychological distress are the conditions that respond best to pharmacological therapy.

Currently, a number of medications are routinely combined or used alone to treat the symptoms of FM, although the US FDA only identified three as effective treatments for FM: Duloxetine, milnacipran, and pregabalin are three selective serotonin and norepinephrine reuptake inhibitors (SNRIs) used to treat depression.

The global market is thus likely to show high growth over the coming years at a CAGR of 8.3% and reach a global market size of US$ 1,182.2 Mn by 2033.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

How Can the Global Fibromyalgia Antidepressants Market Grow?

R&D on Cannabinoid Therapy, and Presence of Low-Cost SNRI Drugs

The cannabinoid system is widely present in the animal kingdom and performs a variety of roles with stabilising benefits for the body, such as with control of pain and stress. By modifying this system, FM treatment may have therapeutic potential. The FM-stabilizing effects of the cannabis system depend on the preservation of equilibrium.

In addition, the endocannabinoid neuromodulatory system has a role in a number of physiological processes, including nausea, antinociception, vomiting, inflammation and immunological recognition, endocrine function, and cognition and memory. FM has been linked to endocannabinoid system deficiencies, but this association lacks strong clinical proof.

With the growth in the research of cannabinoid drugs, the market is expected to be propelled with the increasing research on the therapeutic efficacy of chemical modifications to the endocannabinoid system.

In addition, less research has been done on venlafaxine's effectiveness in the treatment of FM. It is challenging to determine whether venlafaxine is useful in treating FM due to inconsistent dose, absence of placebo control, and blinding. Venlafaxine's tolerability and reduced price, however, improve its potential usage for treating FM by making the drug a more cost-effective alternative to other, more expensive SNRIs.

Availability of low cost drugs for the management of fibromyalgia will further offer the market with lucrative opportunities for expansion, especially in lower and middle-income nations. These factors will propel market growth through the forecasted years.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Can the Fibromyalgia Antidepressants Market Growth Be Affected in Any Way?

Presence of Alternative Therapies

A multidisciplinary strategy incorporates prescription drugs with natural cures, physical or mental exercises, and other interventions. Because of the limited potency of existing therapies, patients frequently turn to alternative therapies for support. Low to moderate levels of improvement in pain and stiffness are seen with acupuncture in FM patients.

In some instances, acupuncture and sham acupuncture have similar effects on pain relief, sleep quality, and overall well-being. Acupuncture is helpful, but its effects are not sustained beyond six months of follow-up. Furthermore, there is not enough proof to support the claim that genuine acupuncture considerably improves quality of life in the short and long term compared to sham acupuncture.

Acupuncture therapy, however, is a secure treatment for FM patients. In addition to acupuncture stimulation, non-invasive neural stimulation using electrical or magnetic currents transmitted to the scalp, such as transcranial electrical or magnetic stimulation, has been used to effectively modulate different brain regions.

Anodal transcranial direct current stimulus over the primary motor cortex has been proven to be significantly efficient than sham direct current transcranial treatment in many instances to reduce pain and enhance overall FM-related performance.

Transcutaneous electrical nerve activation with the transmission of nociceptor stimulus was also explored and found to be an effective factor in the treatment of FM patients, though the mechanisms involved for these results still needs to be explored.

Acupuncture and transcutaneous electric nerve stimulation have both lately been shown to have positive effects on FM patients. Thus, adoption of alternative therapy options will hinder market expansion over the forecasted years.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

Why is the U.S. Market Booming?

“Presence of Regulatory Approved Treatment Modalities”

The U.S. accounted for around 89.1% market share in the North America market in 2022. The US market observes a significant growth traction during the forecast period. This is owed to the rigorous R&D activities, as well as the expansion of pharmaceutical and biopharmaceutical industry within the region.

Duloxetine, MLN, and PGB are three drugs for FMS that the FDA has approved in the US; however, opioids are not authorized for the treatment of fibromyalgia. Health Canada only approved PGB and duloxetine for the treatment of fibromyalgia, making the use of other medications "off-label."

Growing novel product launch and their approval for marketing will set course for the expansion of the market within the country, over the forecasted years.

Will Germany Be a Lucrative Market for Fibromyalgia Antidepressants?

“Existing Recommendations and Guidelines for Treatment of FM by Medical Societies”

Germany held around 24.1% market share of the Europe market in 2022. The most recent recommendations from The Association of the Scientific Medical Societies in Germany (AWMF) (2012), Canadian Pain Society (2012), and European League Against Rheumatism (EULAR) (2016) highlight the shift in perspectives with regard to the overall strategy for treating FM, but they provide varying recommendations with regard to the use of pharmacological agents.

The most popular FM medications are Pregabalin, Duloxetine, and Amitriptyline, which, despite having very limited efficacy, are helpful adjuncts to non-pharmaceutical approaches.

With the presence of established recommendations and guidelines from medical societies in the country, the market is expected to be propelled in terms of growth, over the forecasted years. Moreover, rising awareness of presence of therapeutic modalities, as well as the growing number of product development activities by established organizations in the region will further boost market growth over the projected period.

How is China Emerging as a Prominent Market?

“Growing Disease Awareness and Adoption of Traditional Chinese Medicine”

China held a market share of about 46.4% of the East Asia market in 2022. Fibromyalgia (FM) appears to respond well to traditional Chinese medicine treatments. However, the lack of methodological rigour in the current trials necessitates the design of more large, rigorous investigations.

Moreover, the country is adopting combination therapy approach using traditional Chinese medicine in combination with pharmacologic treatment. Increasing research in the efficacy of traditional Chinese medicine with existing pharmacologic modalities in the country are emerging, thus propelling the demand within the market.

The majority of people in mainland China are unaware of fibromyalgia, and healthcare professionals have a low level of awareness of the condition. Due to their ignorance of fibromyalgia, doctors frequently diagnose patients incorrectly, fail to recognise it as a real medical illness, and/or treat the symptoms with no definitive diagnosis.

Numerous studies indicate that, in part because of a lack of awareness of the condition, the prevalence of fibromyalgia in China may be understated. The most frequently prescribed drugs include amitriptyline, pregabalin, duloxetine, sedatives, NSAIDs, and antidepressants.

The market in China will be further boosted by growing awareness of disease and its treatment options.

Category-wise Insights

Which Antidepressant Drug is Driving Demand within the Global Market?

“Optimal Efficacy and Less Side-Effects”

The duloxetine HCl segment held around 71.6% share of the total market in 2022. Duloxetine eases the discomfort associated with fibromyalgia, as well as other illnesses and ailments, including depression. Instead of an indirect antidepressant impact, a direct analgesic effect accounts for over 90% of the reported effect on pain.

Duloxetine's anxiolytic and antidepressant effects on fibromyalgia patients were not shown in clinical trials to be connected with pain relief. According to the findings of safety studies, duloxetine is both safe and well tolerated. The majority of negative side effects are moderate, more frequent at the beginning of therapy, and gradually become better or go away as treatment continues.

Which Distribution Channel Offers the Market a Profitable Outlook?

“High Disease Incidence and In-Patient Admissions”

Hospital pharmacies held a larger share of about 46.1% in 2022. There is a high burden of disease associated with the prevalence of fibromyalgia. Fibromyalgia continues to affect roughly 4 million US individuals, or 2% of the adults in the United States, according to the U.S. CDC.

Increasing number of hospital admissions for patients with fibromyalgia, as well as the associated length of stay have presented a positive impact on the institutional sales for this segment, thus propelling hospital pharmacies as major distribution channels for fibromyalgia antidepressants.

Moreover, with several countries offering healthcare reimbursement programs, the adoption of treatment for FM is expected to increase, indicating a rise in the institutional sales within the hospital pharmacies, over the forecasted years.

Competition Landscape

The presence of both well-established and up-and-coming market participants distinguishes the global market for fibromyalgia treatments. These players are actively making major investments in research and development to produce cutting-edge treatments. As a result, there is a large pipeline of potential products that are moving forward in clinical studies. Therefore, the availability of therapeutic options with the potential for commercialization is anticipated to boost market growth and aid manufacturers in strengthening their positions in the worldwide market.

Some key instances of development include:

  • The FDA approved Tanezumab, an osteoarthritis medication developed by Eli Lily and Pfizer, in May 2021, as a non-addictive pain reliever for arthritis pain management.
  • In order to acquire the rights to JNJ's oral analgesic JNJ -10450232, which is used to treat moderate to moderately severe acute pain, Neumentum Inc., a pharmaceutical company involved in pain management, entered into a licencing agreement with Janssen Pharmaceuticals NV and McNeil Consumer Pharmaceutical Company (subsidiaries of JNJ) in October 2019.

Similarly, recent developments related to companies manufacturing fibromyalgia antidepressants have been tracked by the team at Persistence Market Research, which is available in the full report.

Fibromyalgia Antidepressants Industry Report Scope

Attribute Details

Forecast Period

2023-2033

Historical Data Available for

2016-2022

Market Analysis

USD Million for Value

Key Countries Covered

  • U.S.
  • Canada
  • Brazil
  • Argentina
  • Mexico
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Russia
  • BENELUX
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Turkey
  • GCC
  • North Africa
  • South Africa

Key Market Segments Covered

  • Antidepressant
  • Distribution Channel
  • End User
  • Region

Key Companies Profiled

  • Pfizer Inc
  • Eli Lilly and Company
  • AbbVie, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson Services, Inc
  • Sanofi
  • GlaxoSmithKline plc.
  • Bayer AG
  • TONIX Pharmaceuticals Holdings Corp
  • Virios Therapeutics, Inc.
  • Aptinyx Inc.
  • FSD Pharma

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Key Segments Covered in Fibromyalgia Antidepressants Industry Research

Drug:

  • Venlafaxine
  • Duloxetine HCl
  • Milnacipran HCl
  • Others

Distribution Channel:

  • Hospitals Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Online Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

- Companies Covered in This Report -

  • Pfizer, Inc.
  • Eli Lilly and Company
  • AbbVie, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson Services, Inc
  • Sanofi
  • GlaxoSmithKline plc.
  • Bayer AG
  • TONIX Pharmaceuticals Holdings Corp
  • Virios Therapeutics, Inc.
  • Aptinyx Inc.
  • FSD Pharma

- Frequently Asked Questions -

The global market is currently valued at around US$ 496.4 Mn in 2022.

Sales of the market are set to witness growth at a CAGR of 8.3% and be valued at around US$ 1,182.2 Mn by 2033.

Demand for the global market increased at a 4.7% CAGR from 2016 to 2022.

U.S., Japan, China, Canada, and Germany account for most demand within the market, currently holding around 64.4% market share.

The U.S. accounts for around 89.1% share of the North American market in 2022.

Latin America accounts for around 8.3% share of the global market in 2022.

China market held a share of about 46.4% in the East Asia fibromyalgia antidepressants market in 2022.

Germany held around 24.1% market share of the Europe market in 2022.

Brazil fibromyalgia antidepressants market is expected to grow at a 10.5% CAGR during the forecast period.

The fibromyalgia antidepressants market in India is set to expand at a 10.8% CAGR over the forecast period.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate